57. Inbrija

Acorda Therapeutics
(Acorda Therapeutics)

Active ingredient: levodopa inhalation powder
Disease: Parkinson’s disease
Peak sales estimate: $600 million by 2026
Approved: Dec. 21
Company: Acorda Therapeutics

The scoop: Earlier this year, a delay to the FDA’s Inbrija decision left some industry watchers wondering whether Acorda could pull off a win for the inhaled Parkinson’s drug, which treats so-called “off” periods where symptoms return. Acorda, though, proved its naysayers wrong, and not a moment too soon for the struggling drugmaker. The company recently lost an appeal to keep generics from taking down lead drug Ampyra, meaning it will rely on Inbrija’s rollout revenue to help fill the gap. Investors will have to hope the company can replicate the “fantastic job” it did “on the Ampyra launch years ago,” Jefferies analyst Michael Yee wrote in a note to clients. — Carly Helfand

57. Inbrija

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.